Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says

Summary by marketbeat.com
Royal Bank Of Canada raised their target price on Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the stock an "outperform" rating in a research report on Thursday.

1 Articles

marketbeat.commarketbeat.com
Center

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says

Royal Bank Of Canada raised their target price on Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the stock an "outperform" rating in a research report on Thursday.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

marketbeat.com broke the news in on Thursday, December 11, 2025.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Royal Bank of Canada icon

Royal Bank of Canada

Stock Markets icon

Stock Markets

Toronto, ON icon

Toronto, ON

Business & Markets icon

Business & Markets

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal